Plavix works in men and women, with differences

* Women mostly benefit from reduced heart attack risk

* More gender-based studies urged

By Julie Steenhuysen

CHICAGO, Nov 9 (Reuters) - The popular blood-thinner Plavix prevents heart attacks and strokes in both women and men, but the benefits differ slightly by gender, U.S. researchers said on Monday.

They analyzed data from five major studies of more than 80,000 people, 30 percent of them women, and found that Plavix or clopidogrel cut the risk of having a heart attack or stroke by 16 percent in men and by 7 percent in women.

The study by Dr. Jeffrey Berger of the New York University School of Medicine offers the first look at gender differences with Plavix -- a $9 billion-a-year seller made by Sanofi-Aventis (SASY.PA) and Bristol-Myers Squibb (BMY.N).

Plavix is used widely in treating heart attack patients. It works in a similar way to aspirin by stopping platelets -- tiny blood cells vital for the normal clotting process -- from clumping together and forming life-threatening clots.

In women, the benefit from Plavix mostly comes from a reduction in the risk of heart attacks, but does it not significantly reduce the risk of stroke or death, Berger and colleagues wrote in the Journal of the American College of Cardiology.

In men, Plavix significantly cut the risk of all three -- heart attacks, stroke and death, they said.